Confronto
Maridebart Cafraglutide vs. Mazdutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
2259884-03-0
Peso molecolare
nessun dato
4790 g/mol
Emivita
nessun dato
132 h
Sequenza
nessun dato
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteMeccanismo d'azione
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
4
Contraddizioni aperte
0
0
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Mazdutide?
- Maridebart Cafraglutide is classified as "Metabolico", while Mazdutide is classified as "Metabolico". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Mazdutide?
- The highest available evidence level is "RCT sull'uomo" for Maridebart Cafraglutide and "RCT sull'uomo" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Mazdutide in Germany and the United States?
- Germania: Maridebart Cafraglutide — Non approvato, Mazdutide — Solo ricerca. Stati Uniti: Maridebart Cafraglutide — Non approvato, Mazdutide — Solo ricerca. These are factual summaries with source and review date on the individual pages.